Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe disease (article text is truncated and omits efficacy/safety numbers). Because key quantitative outcomes and guidance are not provided, the immediate direction of impact on ARWR is unclear. Monitor for reported topline efficacy endpoints, safety/tolerability, and any stated regulatory path following these pivotal readouts.